Follow-up of a Cohort of Patients With Inflammatory Myopathies Associated With a Biobank: MASC 2 Project (Myositis, Muscles, DNA/RNA Serum Cells)

Status: Recruiting
Location: See all (2) locations...
Study Type: Observational
SUMMARY

Myositis are rare diseases for which the development of a cohort associated with a bank of biological samples (biobank) will allow for the conduct of researches to better delineate the underlying pathophysiology and find cures. This prospective cohort of patients with myositis will allow for identification of factors favouring the occurrence of myositis, whether they are constitutional (genetic) or acquired (environmental or drug). Different subgroups of myositis used for prognostication will be identified based on clinico-demographical variables, the nature of the organs involved beyond peripheral muscles (cardiac, diaphragm) and biomarkers abnormalities

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥ 18 years

• Suspicion of Myositis defined according to reference classifications: Dermatomyositis (DM), polymyositis (PM) defined as early as 1975 by Bohan and Peter, inclusion myositis (IM) according to the criteria of Griggs et al, 1995 and autoimmune necrotizing myopathy (ANM) by Hoogendijk et al, in 2004 and iatrogenic (e.g. drug-induced) myositis.

• No opposition from patients to the use of their data

• Signature of consents for the constitution of the biobank and the genetic analyses

Locations
Other Locations
France
Département de médecine interne et immunolgie clinique, Hôpital Pitié Salpêtrière
RECRUITING
Paris
Département de pharmacologie clinique, Hôpital Pitié Salpêtrière
RECRUITING
Paris
Contact Information
Primary
Joe-Elie SALEM, MD PhD
joe-elie.salem@aphp.fr
142178531
Backup
Olivier Benveniste, PU PH
olivier.benveniste@aphp.fr
Time Frame
Start Date: 2022-10-26
Estimated Completion Date: 2057-10-26
Participants
Target number of participants: 4000
Related Therapeutic Areas
Sponsors
Leads: Assistance Publique - Hôpitaux de Paris

This content was sourced from clinicaltrials.gov